Xovoltib 30mg Tablet

• Xovoltib 30mg Tablet is an anticancer medicine. It is prescribed to treat non-small cell lung cancer in the adult patients who have certain mutations of epidermal growth factor receptor (EGFR).
• It contains Afatinib as an active ingredient that works by inhibiting the enzyme receptors to inhibit the growth and multiplication of cancer cells. Take it as prescribed by the doctor at the same time each day.
  

• Non-small cell lung cancer

Like any other anticancer medicine, Xovoltib 30mg Tablet   also shows some side effects, which vary from one person to another according to various health factors. Most of them are mild, and some are serious enough to need immediate medical attention.
Some common side effects include:

• Loose bowels
• Blood in the pee
• Change in the measure of pee
• Quick or sporadic heartbeat
• Mouth aggravation
• Nail issues
• Shortness of breath
• Unordinary weight gain
• Swelling of the hands, arms or legs
• Inconvenience urinating

Seek medical attention in case of any unusual or severe side effects immediately.

• Xovoltib 30mg Tablet is an anticancer medicine available in 20 mg, 30 mg, & 40 mg dosage. Doctor determines the exact dose and duration of the medicine as per patient's health condition. Do not crush or break the tablet.
• In case of an overdose, the doctor will provide emergency medical treatment. Do not stop or change the dose without informing your doctor.
  
  

Xovoltib 30mg Tablet is an anticancer medicine that contains Afatinib as an active ingredient. It works by blocking the action of a protein known as epidermal growth factor receptor (EGFR) that is responsible for the growth and multiplication of certain cancer cells. Results in slowing down the progression of non-small cell lung cancer in patients with specific EGFR gene mutations.

• Yang, J. C., Sequist, L. V., Geater, S. L., Tsai, C. M., Mok, T. S. K., Schuler, M., ... & Wu, Y. L. (2015). Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. The lancet oncology, 16(7), 830-838. https://pubmed.ncbi.nlm.nih.gov/26051236/
• Helena, A. Y., & Pao, W. (2013). Targeted therapies: Afatinib—new therapy option for EGFR-mutant lung cancer. Nature reviews Clinical oncology, 10(10), 551. https://pubmed.ncbi.nlm.nih.gov/23959269/
• Giordano, P., Manzo, A., Montanino, A., Costanzo, R., Sandomenico, C., Piccirillo, M. C., ... & Morabito, A. (2016). Afatinib: An overview of its clinical development in non-small-cell lung cancer and other tumors. Critical reviews in oncology/hematology, 97, 143-151. https://pubmed.ncbi.nlm.nih.gov/26318094/
• Schuler, M., Yang, J. H., Park, K., Kim, J. H., Bennouna, J., Chen, Y. M., ... & Popovych, O. (2016). Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. Annals of Oncology, 27(3), 417-423. https://pmc.ncbi.nlm.nih.gov/articles/PMC4769992/
• Dungo, R. T., & Keating, G. M. (2013). Afatinib: first global approval. Drugs, 73(13), 1503-1515. https://pubmed.ncbi.nlm.nih.gov/23982599/